Tranexamic Acid in Pregnant Women With Placenta Previa
Author Information
Author(s): Muacevic Alexander, Adler John R, Alalaf Shahla, Jawad Ariana K, Al-Tawil Namir G, Dizaye Kawa F, Sileem Sileem A, Elebiary Noor, Mahmood Zanwer S, Khalil Rozhan Y, Amin Khalida M, Ali Nazdaar R
Primary Institution: Hawler Medical University, Kurdistan Higher Council of Medical Specialties, and other hospitals in Iraq and Egypt
Hypothesis
TXA would be safe during pregnancy and decrease the recurrence of vaginal bleeding in women with placenta previa.
Conclusion
TXA treatment during pregnancy significantly reduces vaginal bleeding and improves pregnancy outcomes in women with placenta previa.
Supporting Evidence
- 91.8% of women treated with TXA had bleeding stop compared to 53.4% in the placebo group.
- Women in the TXA group had significantly fewer hospital admissions for blood transfusions.
- Most deliveries in the TXA group were at term, while almost all in the placebo group were preterm.
- TXA was associated with higher rates of live births with normal APGAR scores.
Takeaway
This study shows that a medicine called TXA helps pregnant women with a condition called placenta previa stop bleeding and have healthier babies.
Methodology
A multicenter, randomized, double-blind clinical trial was conducted with 146 women assigned to receive either TXA or a placebo.
Potential Biases
No significant bias risks reported.
Limitations
Heterogeneity in patient characteristics and clinical practices could influence outcomes; larger studies are needed.
Participant Demographics
Pregnant women with placenta previa, aged 28 weeks or more, with recurrent painless vaginal bleeding.
Statistical Information
P-Value
<0.001
Confidence Interval
95% CI = 1.7-15.5
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website